{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:30:35Z","timestamp":1786433435064,"version":"build-2736575974"},"reference-count":99,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"abstract":"<jats:p>\n                    CKD is associated with increased fracture risk and postfracture mortality. CKD-associated osteoporosis arises from the combined effects of traditional pathways (\n                    <jats:italic toggle=\"yes\">e.g<\/jats:italic>\n                    ., age-related bone loss) and CKD-specific mechanisms (\n                    <jats:italic toggle=\"yes\">e.g<\/jats:italic>\n                    ., disturbances in mineral metabolism) that contribute to bone fragility. Dual-energy X-ray absorptiometry, serum calcium, phosphorus, 25-hydroxyvitamin D, parathyroid hormone, and bone turnover markers that are not cleared by the kidneys are used to assess bone health in patients with CKD. Bone biopsy may be used to directly assess bone turnover, mineralization, and volume to guide treatment in patients with advanced CKD. Antiresorptive and anabolic therapies for osteoporosis have demonstrated efficacy and safety in mild to moderate stages of CKD, but there are limited data to guide the use of these drugs in CKD stages 4\u20135. Oral bisphosphonates and denosumab may be effective in advanced CKD, but no study to date has demonstrated a fracture risk reduction in this group. Hypocalcemia and other safety concerns limit the use of denosumab in patients with advanced CKD. Parathyroid hormone analogues and romosozumab demonstrate improvements in bone mineral density in CKD stages 4\u20135, but more data are needed to support the use of these drugs in this population.\n                  <\/jats:p>","DOI":"10.2215\/cjn.0000001149","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:00:07Z","timestamp":1781632807000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Management of Osteoporosis and Low Bone Mass in Kidney Disease"],"prefix":"10.2215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-3279","authenticated-orcid":false,"given":"Matthew","family":"Mulroy","sequence":"first","affiliation":[{"name":"Division of Geriatrics, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Primbas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Primary Care and Population Health, Stanford School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8052-416X","authenticated-orcid":false,"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Weinreb","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-7976","authenticated-orcid":false,"given":"Albert","family":"Shieh","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"3","key":"B1-20260811","doi-asserted-by":"crossref","first-page":"c256","DOI":"10.1159\/000317207","article-title":"Moderate chronic kidney disease in women is associated with fracture occurrence independently of osteoporosis","volume":"116","author":"Kinsella","year":"2010","journal-title":"Nephron Clin Pract."},{"issue":"2","key":"B2-20260811","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archinte.167.2.133","article-title":"Renal function and risk of hip and vertebral fractures in older women","volume":"167","author":"Ensrud","year":"2007","journal-title":"Arch Intern Med."},{"issue":"11","key":"B3-20260811","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1681\/ASN.2005111194","article-title":"Relationship between moderate to severe kidney disease and hip fracture in the United States","volume":"17","author":"Nickolas","year":"2006","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B4-20260811","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/ki.2013.547","article-title":"The three-year incidence of fracture in chronic kidney disease","volume":"86","author":"Naylor","year":"2014","journal-title":"Kidney Int."},{"issue":"2","key":"B5-20260811","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00223-024-01238-9","article-title":"Effect of chronic kidney disease on all-cause mortality after hip fracture surgery: a retrospective cohort study","volume":"115","author":"Jang","year":"2024","journal-title":"Calcif Tissue Int."},{"issue":"4","key":"B6-20260811","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0272-6386(04)00958-8","article-title":"Increased risk of mortality associated with hip fracture in the dialysis population","volume":"44","author":"Mittalhenkle","year":"2004","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B7-20260811","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/j.ajkd.2013.03.009","article-title":"Lifetime incidence of CKD stages 3-5 in the United States","volume":"62","author":"Grams","year":"2013","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B8-20260811","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12882-023-03056-x","article-title":"Prevalence and incidence of chronic kidney disease stage 3\u20135 \u2013 results from KidDiCo","volume":"24","author":"Kampmann","year":"2023","journal-title":"BMC Nephrol."},{"issue":"3","key":"B9-20260811","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","article-title":"Chronic kidney disease\u2013mineral and bone disorder: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"107","author":"Ketteler","year":"2025","journal-title":"Kidney Int."},{"issue":"10","key":"B10-20260811","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00198-003-1454-8","article-title":"A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis","volume":"14","author":"Hernandez","year":"2003","journal-title":"Osteoporos Int."},{"issue":"10","key":"B11-20260811","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S2213-8587(17)30134-1","article-title":"Bone disease in diabetes: another manifestation of microvascular disease?","volume":"5","author":"Shanbhogue","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"26","key":"B12-20260811","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","article-title":"Glucocorticoid-induced osteoporosis","volume":"379","author":"Buckley","year":"2018","journal-title":"N Engl J Med."},{"issue":"7","key":"B13-20260811","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/metabo15070460","article-title":"Fracture risk in chronic kidney disease: addressing an overlooked complication","volume":"15","author":"Gembillo","year":"2025","journal-title":"Metabolites."},{"issue":"8","key":"B14-20260811","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1210\/jcem.86.8.7783","article-title":"Secondary hyperparathyroidism and bone turnover in elderly blacks and whites","volume":"86","author":"Harris","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"B15-20260811","doi-asserted-by":"crossref","first-page":"117108","DOI":"10.1016\/j.bone.2024.117108","article-title":"Secondary hyperparathyroidism: predictors and relationship with vitamin D status, bone turnover markers and bone mineral density","volume":"184","author":"Fitzpatrick","year":"2024","journal-title":"Bone."},{"issue":"8","key":"B16-20260811","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1916","article-title":"Rapid cortical bone loss in patients with chronic kidney disease","volume":"28","author":"Nickolas","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"4","key":"B17-20260811","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/j.ajkd.2020.12.024","article-title":"Osteoporosis and chronic kidney disease\u2013mineral and bone disorder (CKD-MBD): back to basics","volume":"78","author":"Pazianas","year":"2021","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B18-20260811","doi-asserted-by":"crossref","first-page":"e10447","DOI":"10.1002\/jbm4.10447","article-title":"Osteomalacia and vitamin D status: a clinical update 2020","volume":"5","author":"Minisola","year":"2021","journal-title":"JBMR Plus."},{"issue":"suppl ment_3","key":"B19-20260811","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2215\/CJN.02430508","article-title":"The role of bone biopsy in patients with chronic renal failure","volume":"3","author":"Miller","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B20-20260811","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-017-0550-5","article-title":"A comparative study of bone biopsies from the iliac crest, the tibial bone, and the lumbar spine","volume":"18","author":"Hiller","year":"2017","journal-title":"BMC Nephrol."},{"issue":"1","key":"B21-20260811","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int."},{"issue":"4","key":"B22-20260811","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B23-20260811","first-page":"135","article-title":"Adynamic bone disease-bone and beyond","volume":"1","author":"Brandenburg","year":"2008","journal-title":"NDT Plus."},{"issue":"113","key":"B24-20260811","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","author":"Moe","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"B25-20260811","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00774-019-01041-9","article-title":"Bone fracture risk factors in prevalent hemodialysis patients","volume":"38","author":"Matias","year":"2020","journal-title":"J Bone Miner Metab."},{"issue":"3","key":"B26-20260811","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2023","journal-title":"Endocr Rev."},{"issue":"7","key":"B27-20260811","doi-asserted-by":"crossref","first-page":"gfag033","DOI":"10.1093\/ndt\/gfag033","article-title":"Bone turnover markers in the management of CKD-associated osteoporosis - a European consensus","volume":"41","author":"Haarhaus","year":"2026","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"B28-20260811","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J Thorac Oncol."},{"issue":"4","key":"B29-20260811","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5414\/CN109650","article-title":"Serum bone markers in ROD patients across the spectrum of decreases in GFR: activin A increases before all other markers","volume":"91","author":"Lima","year":"2019","journal-title":"Clin Nephrol."},{"issue":"5","key":"B30-20260811","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.ajkd.2021.07.027","article-title":"Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy","volume":"79","author":"J\u00f8rgensen","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"B31-20260811","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1681\/ASN.2017050584","article-title":"Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy","volume":"29","author":"Salam","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B32-20260811","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","author":"Diez-Perez","year":"2017","journal-title":"Osteoporos Int."},{"issue":"1","key":"B33-20260811","doi-asserted-by":"crossref","first-page":"101435","DOI":"10.1016\/j.jocd.2023.101435","article-title":"Executive summary of the 2023 adult position development conference of the international society for clinical densitometry: DXA reporting, follow-up BMD testing and trabecular bone score application and reporting","volume":"27","author":"Shuhart","year":"2024","journal-title":"J Clin Densitom."},{"key":"B34-20260811","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group","volume":"843","year":"1994","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"8","key":"B35-20260811","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1016\/j.transproceed.2019.03.071","article-title":"Pretransplant osteoporosis and osteopenia are risk factors for fractures after kidney transplantation","volume":"51","author":"Lee","year":"2019","journal-title":"Transplant Proc."},{"issue":"7","key":"B36-20260811","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2215\/CJN.12871211","article-title":"Bone mineral density and fracture risk in older individuals with CKD","volume":"7","author":"Yenchek","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B37-20260811","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/jama.2024.27154","article-title":"Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement","volume":"333","author":"Nicholson","year":"2025","journal-title":"JAMA."},{"issue":"6","key":"B38-20260811","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an endocrine society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"B39-20260811","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"issue":"7","key":"B40-20260811","doi-asserted-by":"crossref","first-page":"e1534","DOI":"10.1210\/clinem\/dgad724","article-title":"Trabecular bone score as a marker of skeletal fragility across the spectrum of chronic kidney disease: a systematic review and meta-analysis","volume":"109","author":"Bioletto","year":"2024","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"B41-20260811","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAXTM and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int."},{"issue":"5","key":"B42-20260811","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4158\/GL-2020-0524","article-title":"American association of clinical endocrinologists\/American college of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of Postmenopausal Osteoporosis\u2014 2020 update executive summary","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract."},{"issue":"10","key":"B43-20260811","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int."},{"issue":"2","key":"B44-20260811","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.kint.2018.09.022","article-title":"The fracture risk assessment tool (FRAX\u00ae) predicts fracture risk in patients with chronic kidney disease","volume":"95","author":"Whitlock","year":"2019","journal-title":"Kidney Int."},{"issue":"1","key":"B45-20260811","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00198-013-2524-1","article-title":"The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease","volume":"25","author":"Jamal","year":"2014","journal-title":"Osteoporos Int."},{"issue":"1","key":"B105-20260811","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B46-20260811","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/sdi.12388","article-title":"Pharmacology of bisphosphonates in patients with chronic kidney disease","volume":"28","author":"Ott","year":"2015","journal-title":"Semin Dial."},{"issue":"10","key":"B47-20260811","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures","volume":"161","author":"Crandall","year":"2014","journal-title":"Ann Intern Med."},{"issue":"5","key":"B48-20260811","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"B49-20260811","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jgs.14668","article-title":"Osteoporosis treatment efficacy for men: a systematic review and meta-analysis","volume":"65","author":"Nayak","year":"2017","journal-title":"J Am Geriatr Soc."},{"issue":"1","key":"B50-20260811","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12882-017-0478-9","article-title":"Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials","volume":"18","author":"Shigematsu","year":"2017","journal-title":"BMC Nephrol."},{"issue":"4","key":"B51-20260811","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"3","key":"B52-20260811","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jbmr.2361","article-title":"Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study","volume":"30","author":"Eastell","year":"2015","journal-title":"J Bone Mineral Res."},{"issue":"1","key":"B53-20260811","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","article-title":"Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial","volume":"56","author":"Toussaint","year":"2010","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B54-20260811","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1440-1797.2005.00436.x","article-title":"Effects of short-term alendronate on bone mineral density in haemodialysis patients","volume":"10","author":"Wetmore","year":"2005","journal-title":"Nephrology."},{"issue":"6","key":"B55-20260811","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/jbmr.3676","article-title":"Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial","volume":"34","author":"Iseri","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"85","key":"B56-20260811","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1046\/j.1523-1755.63.s85.21.x","article-title":"Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis","volume":"63","author":"Torregrosa","year":"2003","journal-title":"Kidney Int Suppl."},{"issue":"1","key":"B57-20260811","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int."},{"issue":"17","key":"B58-20260811","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med."},{"issue":"12","key":"B63-20260811","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res."},{"issue":"5","key":"B64-20260811","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of oral bisphosphonates in moderate\u2010to\u2010severe chronic kidney disease: a binational cohort analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J Bone Miner Res."},{"issue":"7","key":"B65-20260811","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/jbmr.4573","article-title":"Oral bisphosphonates are associated with increased risk of severe acute kidney injury in elderly patients with complex health needs: a self\u2010controlled case series in the United Kingdom","volume":"37","author":"Oda","year":"2022","journal-title":"J Bone Miner Res."},{"issue":"1","key":"B66-20260811","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11914-005-0021-y","article-title":"Treatment of osteoporosis in chronic kidney disease and end-stage renal disease","volume":"3","author":"Miller","year":"2005","journal-title":"Curr Osteoporos Rep."},{"issue":"3","key":"B67-20260811","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1053\/j.ajkd.2021.06.031","article-title":"Diagnosis and management of osteoporosis in advanced kidney disease: a review","volume":"79","author":"Ginsberg","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"B68-20260811","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5414\/CN110993","article-title":"Treatment of bone loss in CKD5D: better survival in patients with non-high bone turnover","volume":"98","author":"Malluche","year":"2022","journal-title":"Clin Nephrol."},{"issue":"5","key":"B69-20260811","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MNH.0000000000001091","article-title":"Agents to treat osteoporosis in chronic kidney disease","volume":"34","author":"Khairallah","year":"2025","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"6","key":"B70-20260811","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s11914-018-0491-3","article-title":"Updates in CKD-associated osteoporosis","volume":"16","author":"Khairallah","year":"2018","journal-title":"Curr Osteoporos Rep."},{"issue":"8","key":"B71-20260811","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Min Res."},{"issue":"2","key":"B72-20260811","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","article-title":"Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease","volume":"106","author":"Broadwell","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"B73-20260811","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2215\/CJN.0000000000000213","article-title":"Long-term effect of denosumab on bone disease in patients with CKD","volume":"18","author":"Iseri","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B74-20260811","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1038\/s41598-020-59143-8","article-title":"Denosumab for dialysis patients with osteoporosis: a cohort study","volume":"10","author":"Kunizawa","year":"2020","journal-title":"Sci Rep."},{"issue":"10","key":"B75-20260811","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s11255-024-04110-9","article-title":"Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting","volume":"56","author":"Simonini","year":"2024","journal-title":"Int Urol Nephrol."},{"issue":"2","key":"B76-20260811","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/ANNALS-24-03237","article-title":"Cardiovascular safety and fracture prevention effectiveness of denosumab versus oral bisphosphonates in patients receiving dialysis: a target trial emulation","volume":"178","author":"Masuda","year":"2025","journal-title":"Ann Intern Med."},{"issue":"7","key":"B77-20260811","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Min Res."},{"issue":"5","key":"B78-20260811","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/jbmr.4804","article-title":"Hypocalcemia risk of denosumab across the spectrum of kidney disease: a population-based cohort study","volume":"38","author":"Cowan","year":"2023","journal-title":"J Bone Min Res."},{"issue":"1","key":"B79-20260811","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/M24-0013","article-title":"The effect of denosumab on risk for emergently treated hypocalcemia by stage of chronic kidney disease","volume":"178","author":"Bird","year":"2025","journal-title":"Ann Intern Med."},{"issue":"6","key":"B80-20260811","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA."},{"issue":"1","key":"B82-20260811","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11657-021-00971-0","article-title":"Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety","volume":"16","author":"Gopaul","year":"2021","journal-title":"Arch Osteoporos."},{"key":"B83-20260811","doi-asserted-by":"crossref","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","article-title":"Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider","volume":"130","author":"Tripto-Shkolnik","year":"2020","journal-title":"Bone."},{"issue":"4","key":"B84-20260811","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"B85-20260811","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporos Int."},{"issue":"7","key":"B86-20260811","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"B88-20260811","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3803\/EnM.2024.2125","article-title":"Long-term efficacy and safety of denosumab: insights beyond 10 years of use","volume":"40","author":"Ha","year":"2025","journal-title":"Endocrinol Metab."},{"issue":"10169","key":"B87-20260811","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet."},{"issue":"19","key":"B89-20260811","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"issue":"7","key":"B90-20260811","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"B91-20260811","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int."},{"issue":"12","key":"B92-20260811","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","article-title":"Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial","volume":"35","author":"Bilezikian","year":"2019","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"B93-20260811","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000316708","article-title":"Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study","volume":"33","author":"Cejka","year":"2010","journal-title":"Kidney Blood Press Res."},{"issue":"4","key":"B94-20260811","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","article-title":"Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study","volume":"27","author":"Sumida","year":"2016","journal-title":"Osteoporos Int."},{"issue":"3","key":"B95-20260811","doi-asserted-by":"crossref","first-page":"254","DOI":"10.25259\/ijn_555_23","article-title":"Teriparatide improves bone formation markers and bone mineral density in adynamic bone disease associated with chronic kidney disease","volume":"34","author":"Jha","year":"2024","journal-title":"Indian J Nephrol."},{"issue":"11","key":"B96-20260811","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","article-title":"Efficacy and safety of human parathyroid hormone-(1\u201384) in increasing bone mineral density in postmenopausal osteoporosis","volume":"88","author":"Hodsman","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"16","key":"B97-20260811","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"issue":"15","key":"B98-20260811","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med."},{"issue":"9","key":"B99-20260811","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"B100-20260811","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/jbmr.4563","article-title":"Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease","volume":"37","author":"Miller","year":"2022","journal-title":"J Bone Miner Res."},{"issue":"6","key":"B101-20260811","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","article-title":"Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study","volume":"39","author":"Sato","year":"2021","journal-title":"J Bone Miner Metab."},{"issue":"1","key":"B102-20260811","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","article-title":"One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study","volume":"112","author":"Saito","year":"2023","journal-title":"Calcif Tissue Int."},{"issue":"3","key":"B104-20260811","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:00:21Z","timestamp":1786431621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":99,"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001149","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}